Product Code: 1475-083X
BMI View: The use of enduring drug-delivery implants will increase in the long-term as they provide a solution to overcome the prevalent issues of non-compliance, particularly as the burden from chronic diseases increases. However, short-term pressures from cyber security, risks from leakages, and a lack of infrastructure to cater for the implementation will limit near-term uptake.
Table of Contents
- Compliance Burden Key Driver For Drug-Delivery Implants Corporate News
- Agreements
- Nucynta Deal Will More Than Double Depomed's Annual Net Product Sales
- Vectura/Janssen Sign Deal To Develop Anti-Inflammatory Therapy
- Seattle Genetics/BMS Enter Clinical Trial Collaboration For Adcetris/Opdivo
- Vect-Horus/Sanofi Enter Collaboration For Neurodegenerative Diseases
- Corporate Activities
- Hospira Unveils Progress On Global Device Strategy
- BioLight Invests In Newly-Formed Ophthalmic Company Product News
- Product Approvals
- FDA Clears t:flex Insulin Pump With Expanded Reservoir
- FDA Approves AbbVie's Duopa For Motor Fluctuations In Advanced PD Patients
- La Fenice Insulin Pump Gains Re-Registration Approval In China
- Flowonix Gains Supplemental PMA For Next-Generation Intrathecal Infusion Device R&D
- Medical Devices Appetite Growing For 3D Printing
- Enrolment Begins In Tyrx Absorbable Antibacterial Envelope Trial For CIEDs Infections
- Novartis Reports Positive Results From Phase III COPD Studies
- First Of Three Sativex Phase III Cancer Pain Trials Misses Primary Endpoint
- Photocure Concludes End Of Phase II Status For Cevira In US
- Patents
- NSAID Market Set To Welcome Encapsulated Equivalents
- Oramed Granted Patent In Israel Covering Exenatide
- Actavis Challenges US Abstral Patents
- Regulatory Filings
- Sacituzumab Govitecan Gains FDA Fast Track Designation For TNBC
- LEO Submits NDA For Calcipotriene+Betamethasone Aerosol Foam In Plaque Psoriasis
- Neos Submits NDA For Methylphenidate XR-ODT For ADHD
